Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6D78

The complex between high-affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with the bound MART-1(27-35)peptide

6D78 の概要
エントリーDOI10.2210/pdb6d78/pdb
分子名称HLA class I histocompatibility antigen, A-2 alpha chain, Beta-2-microglobulin, Melanoma antigen recognized by T-cells 1, ... (6 entities in total)
機能のキーワードalpha-beta t-cell receptor bound to class i mhc (hla-a2) in complex with the mart-1 peptide, immune system
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数5
化学式量合計93997.49
構造登録者
Hellman, L.M.,Singh, N.K. (登録日: 2018-04-24, 公開日: 2019-04-03, 最終更新日: 2024-10-30)
主引用文献Hellman, L.M.,Foley, K.C.,Singh, N.K.,Alonso, J.A.,Riley, T.P.,Devlin, J.R.,Ayres, C.M.,Keller, G.L.J.,Zhang, Y.,Vander Kooi, C.W.,Nishimura, M.I.,Baker, B.M.
Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.
Mol. Ther., 27:300-313, 2019
Cited by
PubMed Abstract: T cell receptors (TCRs) have emerged as a new class of immunological therapeutics. However, though antigen specificity is a hallmark of adaptive immunity, TCRs themselves do not possess the high specificity of monoclonal antibodies. Although a necessary function of T cell biology, the resulting cross-reactivity presents a significant challenge for TCR-based therapeutic development, as it creates the potential for off-target recognition and immune toxicity. Efforts to enhance TCR specificity by mimicking the antibody maturation process and enhancing affinity can inadvertently exacerbate TCR cross-reactivity. Here we demonstrate this concern by showing that even peptide-targeted mutations in the TCR can introduce new reactivities against peptides that bear similarity to the original target. To counteract this, we explored a novel structure-guided approach for enhancing TCR specificity independent of affinity. Tested with the MART-1-specific TCR DMF5, our approach had a small but discernible impact on cross-reactivity toward MART-1 homologs yet was able to eliminate DMF5 cross-recognition of more divergent, unrelated epitopes. Our study provides a proof of principle for the use of advanced structure-guided design techniques for improving TCR specificity, and it suggests new ways forward for enhancing TCRs for therapeutic use.
PubMed: 30617019
DOI: 10.1016/j.ymthe.2018.12.010
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.347 Å)
構造検証レポート
Validation report summary of 6d78
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon